Accelerating drug discovery by industrializing data & AI Governance
HYGHT is defining a data and AI governance strategy to address mounting data challenges, including rapid growth, departmental isolation causing data silos, navigating diverse regulations, and the increasing use of AI models for drug discovery. This effort aligns with the EU AI Act’s requirements, aiming to enable seamless data access, foster collaboration, and ensure regulatory compliance, empowering effective AI and data analytics utilization.
at a glance
Getting ready for scaling AI
- Data Volume and Integration: Managing the substantial increase in data volume while ensuring seamless integration into solution delivery streams and addressing strategic objectives.
- Departmental Isolation and Implementation: Overcoming the challenges posed by isolated departments to ensure practical implementation of a governance framework through actionable and integrated solutions.
- Regulatory Hurdles, AI Complexity, and Compliance: Navigating diverse regulatory landscapes, managing the increased complexity of AI models for drug discovery, and aligning with the requirements of the EU AI Act while developing a comprehensive approach to data and AI governance.
-
Data Challenge Identification: Conducted a comprehensive assessment to identify current data challenges, including volume, isolation, regulatory hurdles, and AI model complexity.
-
Holistic Data Governance Framework Design: Developed a robust framework addressing seamless integration, regulatory compliance, and effective AI system management.
-
Use Case Selection and PoC: Executed a Proof of Concept (PoC) to validate the data governance framework before scaling.
-
EU AI Act Compliance: Examined EU AI Act requirements, documenting AI systems and models for alignment with regulations.
-
AI Governance Development: Designed and operationalized an AI governance framework, establishing an AI governance council for system management and compliance.
- Accelerated Drug Discovery: Streamlined data access accelerated drug discovery, fostering innovation.
- EU AI Act Compliance: Ensured regulatory adherence and mitigated risks through alignment with EU AI Act requirements.
- New Use Cases Enabled: Reusable AI models unlocked innovation and facilitated new use cases.
- Enhanced Accountability: Clear role definitions improved operational efficiency and accountability.
- Amplified Business Value: Accurate, compliant, and consistent data increased business value and informed decision-making.
Project Highlights
